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1 Summary 
 
  The production rate of thyroid hormones (TH) by thyroid gland is regulated by 
the hypothalamus-hypophysis-thyroid axis in order to maintain a highly stable plasmatic 
hormone concentration, needed for the basal metabolic activity of target tissues (1). On 
the contrary, the intracellular concentration of TH, namely triiodothyronine (T3) and 
thyroxine (T4), is subjected to dramatic changes in response to tissue-specific metabolic 
requests (2). The peripheral metabolism of TH is finely regulated by the deiodinase 
family of selenoproteins. Type 1 and type 2 deiodinases (D1 and D2) mediate the 
activation of the pro-hormone T4 into the active form T3 (3-5), while the type 3 
deiodinase (D3) inactivates both T4 and T3 (6, 7). The 80% of T3 production derives 
from peripheral T4 to T3 deiodination (8). D2 represents the major source of T3 in 
humans, with a 700-fold greater catalytic efficiency compared to D1 (3). No mutations 
in D2 have been reported yet, but over the last few years several single nucleotide 
polymorphisms (SNP) have been identified (9). Among these, the SNP Thr92Ala 
(rs225014) of DIO2 gene is founded to be present in the general population with a 
prevalence that ranges between 12.9 and 14.9% (10-12). Since its identification in 2002, 
the clinical role of the D2-Ala isoform has been a matter of debate. Particularly, it has 
been speculated a possible relationship between reduced D2 activity and persistence of 
hypothyroid-like symptoms in athyreotic levothyroxine (LT4)-treated patient (13-16). 
However, to date, no clear association between Thr92Ala and reduced T3 levels has 
been yet demonstrated.  
  Aim of this study is to assess the biochemical and clinical significance of the 
Thr92Ala DIO2 gene polymorphism. To this end, we investigated the effects of 
Thr92Ala mutation in two biological models of D2-dependent tissues, namely, muscle 
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stem cells and pituitary thyrotrophs. We demonstrated that the T4 to T3 conversion 
mediated by D2-Ala is reduced compared to D2-WT, since the T4 action in cells 
expressing D2-Ala resulted significantly impaired. In addiction, we compared the 
presurgical with the postsurgical TH levels profile in 140 patients subjected to total 
thyroidectomy and on levothyroxine monotherapy, and analyzed the DIO2 gene status 
in a subgroup of 102/140 of patients. We found that mean postsurgical FT3 levels were 
significantly lower than before surgery in patients carrying genotype DIO2Ala/Ala-WT 
compared to wild-type patients. In conclusion, this study provides the first evidence 
that the SNP Thr92Ala reduces the D2 enzymatic activity, supporting a customized 
treatment of hypothyroidism in athyreotic patients who complain hypothyroidism-like 
symptoms with LT4-only replacement therapy. 
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2 Background 
 
2.1 Intracellular metabolism of thyroid hormones 
  The peripheral control of thyroid hormones (TH) action is coordinated by 3 
interconnected cellular systems: membrane transporters, deiodinases and TH nuclear 
receptors (2, 17, 18). TH transporters regulate the inflow and outflow of TH between 
cell and blood flow (19). Several TH transporters with different ligand affinities and 
tissue distribution have been identified. Among these, high specificity for TH has been 
demonstrated for monocarboxylate transporter 8 (MCT8) and MCT10, and organic 
anion transporting polypeptide 1C1 (OATP1C1) (20, 21). MCT8 is mainly expressed in 
liver, cardiac muscle, placenta and brain (hypothalamus and third ventricle)	 (22, 23). 
MCT10 is ubiquitously expressed and has a preference for T3, mediating the T3 inflow 
with a greater extent than MCT8 (24). OATP1C1 shows the highest ligand specificity 
for iodothyronines among the OATPs family members. This transporter has been 
founded in the hematoencephalic barrier and shows preferential inflow of T4. However, 
his relevance in TH transport is still unclear (25, 26).  
  The deiodinase selenoproteins D2 and D3 are responsible for the intracellular 
activation and inactivation of TH (3). The 5'-deiodination of the pro-hormone T4 is 
crucial for TH action and depends on the activity of D2. D2 localizes in the 
endoplasmic reticulum, in order to provide a prompt availability of T3 for the nuclear 
transcriptional activity of TRs	 (27). Its activity is founded in thyroid, skeletal and 
cardiac muscle, placenta and brain (28, 29). D3 is located on the cell membrane and 
mediates the inactivation of T4 into biologically inefficient reverse T3 (rT3) and of T3 
into the inactive hormone T2 (6, 30). D1 is located in the inner surface of the plasma 
membrane and provides a significant portion of the circulating plasma T3	 (31). D1 
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shows a remarkable preference for outer ring deiodination of rT3. Therefore, its role in 
humans is thought to be as a scavenger enzyme to remove inactive iodothyronines from 
the blood flow and recycle the iodine molecules (4, 32).   
  TH receptors are members of the superfamily of nuclear receptors and acts as 
T3-inducible transcription factors	 (33). Two genes, TRα e TRβ, located in 2 different 
chromosomes, encodes for 4 T3-binding isoforms: α1, β1, β2 e β3 (34). The TRs act on 
specific thyroid hormone response elements (TREs) located on the promoter regions of 
T3-target genes	 (35). The expression of TRs is tissue and time-specific, depending on 
developmental cells stage (36). Moreover, TRs activity is modulated in a T3-dependent 
fashion by several regulatory proteins	(37). 
 
2.2 Role of deiodinases in muscle stem cells proliferation and development 
  TH are key players of muscle stem cells (MuSC) proliferation and 
development (38-40). The MuSC differentiation toward the myogenic phenotype is 
triggered by the transcriptional activity of Paired-box 3 (PAX3) and maintained by the 
expression of PAX7. Both PAX3 and 7 are master regulators of the Myogenic 
Regulation Factors (MRFs), a group of basic-helix-loop-helix transcription factors that 
sequentially modulate the differentiation of muscle cells (41). PAX3 is highly active 
during the embryofetal development and is silenced after birth in almost all muscle 
groups. PAX7 is involved in post-natal muscle development, particularly in 
maintenance of the undifferentiated state of stem cells (42). In skeletal muscle, stem 
cells are located between basal lamina and sarcolemma and are therefore called satellite 
cells (43). Satellite cells express PAX7 and are normally in a quiescent state. However, 
they activate in response to different stimuli such as physical exercise, damage or 
muscle diseases (44). Once activated, stem cells compartment expands becoming 
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myoblasts, i.e. proliferating cells that differentiate through the myogenic line. Satellite 
cells activation requires the up-regulation of two MRFs: Myogenic Factor 5 (MYF5) 
and Myogenic Differentiation Protein 1 (MyoD). PAX3 and PAX7 directly bind to the 
MyoD promoter and act as distant enhancer elements for MYF5 (45, 46). 
  The activity of PAX proteins and the induction of the muscle-specific genetic 
program that determines the myogenic differentiation are stimulated by T3 (38). Most 
of MRFs, including MyoD, host within their promoter regions thyroid response 
elements. Therefore, T3 is able to modulate the expression of key genes of muscle 
development (47, 48). The intracellular T3 concentration is supplied by two distinct 
sources. The first is represented by plasma T3, that enters through TH transporters. The 
second, by intracellular TH activation mediated by D2. Since TH plasma levels are 
highly constant, deiodinases are essential to provide rapid and significant TH variations, 
in order to modulate the TH signaling according to peripheral cellular requirements (39, 
49-51). 
  The early proliferation phases of MuSC depend on the activity of D3 (52). D3 
expression occurs in activated and proliferating MuSC and rapidly decline before the 
start of differentiation. This expression profile is crucial for the expansion of stem cells 
compartment (53). In human adults, MuSC are mainly activated after injury during 
repair processes. Evidences provided by D3KO mice subjected to muscle damage 
showed that D3 depletion causes massive apoptosis of PAX7+ activated cells compared 
to WT controls. MuSC apoptosis is consequent to the exposure to elevated TH levels 
during the activation phase. Therefore, D3 is considered a survival factor for activated 
stem cells (52, 54).  
  Along the differentiation program of activated MuSC, D2 shows an opposite 
expression pattern. D2 is expressed in myoblasts precursors and highly induced during 
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differentiation. The increase in intracellular T3 promotes MYOD gene expression, 
allowing the progression of cell line towards myocytes (54). The role of D2 in 
myoblasts is demonstrated by experiments from DIO2 knock-out mice cells. DIO2-/- 
cells show reduced MyoD levels compared to WT (47). The impairment in MyoD 
signaling causes an increase in the number of proliferating myoblasts, since cells are 
unable to complete the differentiation in myocytes. High T3 doses or MyoD 
overexpression in DIO2-/- cells are able to rescue the lineage progression and to 
complete cellular differentiation (54). Therefore, D2 is responsible for the T3 increase 
needed to the up-regulation of MyoD, essential for the completion of myogenic 
developmental program.  
 
2.3 Clinical implications of T92A polymorphism of type 2 deiodinase  
  The SNP rs225014 A→G in exon 2 of DIO2 gene determines the substitution 
of a threonine (Thr, T) with an alanine (Ala, A) in position 92 of D2 protein. Among the 
general population, the prevalence of homozygous D2Ala/Ala ranges from 10 to 13% (10-
12). The T92A SNP was firstly identified in a study from Mentuccia et al. in 2002 (55). 
In this study, D2-Ala expression was founded to be related to reduced glucose disposal 
rate and higher fasting glucose in a group of 115 obese non-diabetic women, compared 
to controls. Since then, T92A has been connected to many clinical situations, 
speculating that D2-Ala causes reduced activity in T4 to T3 conversion (13, 56-60). 
However, enzymatic activity assays on D2-Ala has been performed only in a few 
studies, and results are conflicting. Canani et al. (56) reported a lower enzyme velocity 
in muscle and thyroid samples from patients (pts) with homozygous expression of D2-
Ala, compared to Ala/Thr and Thr/Thr groups. Nevertheless, in this study there was no 
differences between isoforms in an in vitro model of HEK293 cells. Similarly, an 
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activity assay performed in a recent study from McAninch et al. (61) found no 
differences in catalytic velocity of D2-Ala protein.  
  The D2-Ala isoform seems to impair glucose metabolism and TH replacement 
therapy	 (16, 62). In fact, several studies showed an association between the expression 
of D2Ala/Ala and insulin resistance. Mentuccia et al. (55) founded a reduced glucose 
disposal rate in pts expressing D2Ala/Ala subjected to euglycemic-hyperinsulinemic 
clamp, compared to controls. Canani et al. (56) demonstrated a greater insulin resistance 
in pts with type 2 diabetes mellitus (T2DM) expressing the Ala/Ala genotype compared 
to A/T and T/T. Moreover, the prevalence of homozygous D2-Ala in T2DM pts was 
higher than in general population (i.e. 19.1%). Similarly, in a case-control study 
involving 1057 T2DM pts and 516 controls, Dora et al. (57) reported a frequency of 
D2Ala/Ala of 16.4% versus 12% in T2DM pts versus controls, respectively. In this report, 
the homozygous expression of Ala genotype was associated to increased insulin levels 
and worst glycemic control. A greater prevalence of D2Ala/Ala in T2DM pts was founded 
also in other 3 population studies. The Amish Family Diabetes Study (10) reported a 
prevalence of D2-Ala genotype of 12.7% (16/126) versus 9.4% in non diabetics 
(66/703). A study from Maia et al. (12) performed D2 genotyping in 1633 participants 
from the Offspring Cohort of the Framingham Heart Study. The authors founded a 
prevalence for D2Ala/Ala of 14.8% in T2DM compared to 12.4% in controls. Lastly, 
Grarup et al. (11) analyzed D2 genotype in 7000 white Danish subjects, of whom 5595 
were non diabetics and 1405 were affected by T2DM. The prevalence of homozygous 
expression of D2-Ala was 12.8% and 13.7%, respectively. 
  The first evidence of altered TH homeostasis in patients expressing D2-Ala is 
from Torlontano et al. (13). In a study conducted on 191 pts subjected to total 
thyroidectomy followed by radioiodine thyroid ablation, the authors showed that 
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D2Ala/Ala pts needed significantly higher doses of LT4 to suppress TSH, compared to 
D2X/Thr subjects. However, a subsequent report from Heemstra et al. (63) analyzing the 
effect of D2-Ala expression in 154 athyreotic pts on LT4 therapy didn't show any 
association between T92A genotype and TSH levels. Butler et al. (14) evaluated 
changes in T3 levels after TRH-stimulation of pituitary gland in 15 pts with Ala/Ala 
genotype, compared to 30 pts with X/Thr. The study showed that the rise in T3 levels 
after TSH-stimulated hormone release in pts expressing the D2Ala/ Ala isoform is 
reduced. 
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3 Aim of the study 
 
  A substantial proportion of athyreotic levothyroxine (LT4)-treated patients 
experiences hypothyroid-like symptoms (64-66).	 In normal subjects, the daily 
production rate of T3 is 20% dependent on thyroid gland secretion and 80% on 
extrathyroidal T4 deiodination (2). On the contrary, during LT4 replacement, levels of 
the active hormone T3 comes only from D2-mediated activation of LT4 (67). The T92A 
polymorphism in the DIO2 gene has been associated with various clinical conditions. 
Notably, it has been speculated a possible relationship between reduced D2 activity and 
persistence of hypothyroid-like symptoms in patients on LT4 replacement therapy (16, 
66, 68). However, although clinical studies suggest that the SNP T92A may impair D2 
enzyme activity	 (11, 14, 15, 56, 57, 69-72), a clear association between D2-Ala 
expression and reduced tissue T3 levels has not been established	(73).  
  Aim of this study is to assess the biochemical and clinical significance of the 
T92A DIO2 gene polymorphism. In previous studies, D2-Ala activity was found to be 
reduced in patients homozygous for the Ala allele (56); however, that findings may 
have been related to artifacts intrinsic to the D2 activity in vitro assay (67, 73). To 
overcome the limitations of the D2 in vitro assay, we developed two biological models 
for an in vivo D2 enzymatic assay, namely, muscle stem cells and thyrotrophs from 
Dio2-null mice. The use of intact cells more closely resembles the in vivo situation and 
enabled us to identify a functional limitation resulting from the D2-Ala mutation. In 
addiction, we compared the presurgical with the postsurgical TH status in a group of 
140 thyroidectomized patients on standard levothyroxine monotherapy, and analyzed 
their DIO2 genotype. The analysis was conducted in patients that had similar 
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presurgical and postsurgery TSH levels, thus allowed us to evaluate putative changes in 
circulating TH levels with the same feedback set point.  
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4 Materials and methods 
 
4.1 Patient selection 
  Patients submitted to total thyroidectomy were candidates for this study. 
Inclusion criteria were thyroid profile data obtained within 10 months of surgery and a 
postsurgery thyroid profile obtained at least 6 months after achievement of a stable TH 
status on LT4 therapy. In addition, pre-surgery and post-surgery serum TSH levels 
should not differ by more than ±0.5 mIU/L. We excluded patients with an abnormal 
thyroid profile (hypo- or hyperthyroidism) before surgery, patients receiving drugs that 
could interfere with thyroid function, and patients affected by malabsorption-related 
conditions. Based on these criteria, we recruited 140 patients for the study (72.1% 
females) with a mean age of 54.4 6 14.9 years (range, 18 to 84 years) and with 
uninodular (73/140, 37.9%) or multinodular goiter (67/140; 62.1%). At final histology, 
17/140 (12%) patients had a benign goiter and 123/140 (88%) had differentiated thyroid 
carcinoma. Immediately after surgery, patients were treated with LT4 to obtain 
comparable presurgical TSH levels, with a mean dose of 114.9 mcg/d and a mean 
dose/kg of 1.54 mcg of LT4. Fasting blood samples were collected at 8 AM to 9 AM 
before patients assumed the LT4 tablet, and all determinations were performed with a 
chemiluminescent immunometric assay (Access Immunoassay Systems 2006, Beckman 
Coulter, Milan, Italy). Normal ranges in our laboratory were 2.5 to 4.1 pg/mL for free 
T3 (FT3), 5.8 to 16.4 pg/mL for free thyroxine (FT4), and 0.4 to 4.0 mIU/L for TSH. In 
our laboratory, the interassay variation of the FT3 assay was 8%, which corresponds to 
±0.26 pg/mL. Thus, we arbitrarily selected a change of at least 0.5 pg/mL as a 
significant variation between pre- and postsurgical FT3 value. 
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4.2 DIO2 gene analysis 
  For gene analysis, 102/140 (72.8%) patients agreed to donate a blood sample 
for genetic testing. Each patient provided written informed consent to the study. 
Genomic DNA was extracted with the QIAamp DNA Micro Kit (Qiagen, Milan, Italy) 
according to the kit’s instructions. DNA concentration was assessed with a fluorometer 
(GloMax Multi Jr, Promega, Milan, Italy). Primers were designed to cover all DIO2 
exons, the intron/exon junctions, and the 50-UTR region for the analysis of the 2258 
G/A (rs12885300) polymorphism using Primer 3 (version 0.4.0). Annealing temperature 
was 60°C and 51°C (35 cycles), respectively, for exons and for the 50-UTR (MgCl2 
concentration ranged from 1.5 to 2.5 mM). In the case of exons, polymerase chain 
reaction (PCR) products were analyzed with denaturing high-performance liquid 
chromatography at specific temperatures to verify the presence/absence of 
mutations/polymorphisms. Positive samples were subjected to direct sequencing 
(Genechron, Rome, Italy). For 2258 G/A, PCR products were digested with the CviKI-1 
restriction enzyme (New England Biolabs, Milan, Italy) at 37°C overnight. Fragments 
were run in a 3% agarose gel stained with ethidium bromide. Genotype determination 
on the gel was: wild-type subjects showed three fragments at 117, 24, and 4 bp; 
heterozygous had four fragments at 145, 117, 24, and 4 bp; and mutant homozygous 
showed a single 145-bp-long fragment. The restriction fragment length polymorphism 
genotyping method was verified by a 100% concordance rate after random sequencing 
15% of the sample. 
 
4.3 Cell cultures and transfections 
  Muscle stem cells were prepared for fluorescence activated cell sorting (FACS) 
analysis using a FACSARIA cell sorter (BD Biosciences, San Jose, CA) and cultured in 
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1:1 Dulbecco’s modified Eagle medium (Gibco Life Technologies, Paisley, UK) and 
MCDB-201 medium (Sigma-Aldrich, Saint Louis, MO) containing 20% fetal bovine 
serum (Gibco) and insulin transferrin selenium (Gibco). Cells were plated on matrigel 
(BD Biosciences) and kept in an incubator (37.0°C, 6.5% CO2, 3% O2). Thyrotrophs 
were isolated from the pituitary gland of Dio2-null mice according to the protocol 
reported by Luongo et al. (74). Transient transfections were performed using 
Lipofectamine 2000 (Invitrogen Life Technologies, Carlsbad, CA) according to the 
manufacturer’s instructions. Cells were then cultured in Dulbecco’s modified Eagle 
medium with an addition of 10% fetal bovine serum. 
 
4.4 Plasmids and reagents 
  T3-T4 and rT3 were purchased from Sigma-Aldrich and used at a 30-nM 
working concentration. Cycloheximide was from Sigma-Aldrich and used at a 10-mM 
concentration. 
 
4.5 Western blot analysis 
  Total protein extracts from cells and tissues were run on a 10% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis gel and transferred to an Immobilon-P 
transfer membrane (Millipore, Billerica, MA). The membrane was then blocked with 
5% nonfat dry milk in phosphate buffered saline, probed with anti-Flag antibody 
(1:1000, M2-Sigma) or PARP antibody (1:500, Cell Signaling, Danvers, MA) for 2 
hours, washed and incubated with horseradish peroxidase–conjugated donkey anti-
rabbit or mouse immunoglobulin G secondary antibody (1:3000), and detected by 
chemiluminescence (Millipore). After extensive washing, the membrane was incubated 
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with antitubulin-specific antibody (1:10,000; sc-8035, Santa Cruz, Dallas, TX) as 
loading control. All Western blots were run in triplicate. 
 
4.6 Immunofluorescence 
  For immunofluorescent staining, cells were fixed with 4% formaldehyde and 
permeabilized in 0.1% Triton X-100, then blocked with 0.5% goat serum and incubated 
with primary antibody. AlexaFluor 595- or 488-conjugated secondary antibody was 
used. Immunofluorescence labeling was evaluated with a Zeiss 510 confocal laser 
scanner microscope and with an IX51 Olympus microscope and the Cell*F software. 
Images were assembled using Adobe Photoshop. 
 
4.7 Statistics 
  For epidemiological data (presented as mean ± standard deviation) and DIO2 
polymorphism analysis, we used GraphPad Prism 4. The paired t test was used to 
analyze normally distributed data, and the Wilcoxon and the Mann-Whitney tests were 
used to analyze not normally distributed data. We used contingency tables to evaluate 
substantial differences in data frequency. One-way analysis of variance with Dunnett 
post hoc test was used for multiple comparisons. For basic experiments, differences 
between samples were assessed with the Student two-tailed t test for independent 
samples. Errors are reported as standard error of the mean throughout. Differences were 
considered significant when P was <0.05 (*P <0.05, **P <0.01, and ***P <0.001). 
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5 Results 
 
5.1 D2 expression in proliferating myoblasts is critical for TH-induced 
proapoptotic effect 
  In muscle stem cells (MuSC), type 2 and type 3 deiodinases are active and 
differentially expressed along cell maturation. During the proliferating phase, myoblasts 
overexpress D3 to achieve a low intracellular TH signaling, essential to permit the 
correct cell amplification. Active D2 is still present in proliferating myoblasts but its 
activity is counteracted by the abundant D3 expression. Indeed, previous reports 
showed that D3-depletion lead to apoptosis of activated proliferating myoblasts due to 
temporary TH excess. To assess whether forced amounts of D2 might disrupt the 
balance of intracellular TH and cause apoptosis, we transfected proliferating myoblasts 
with D2 under normal serum conditions. D2 overexpression caused dose-dependent 
apoptosis, as demonstrated by PARP cleavage, thus confirming that cell death depends 
on a D2-dependent increase in intracellular T3 (Figure 1A). To confirm the upstream 
role of intracellular D2-mediated T4 activation, proliferating myoblasts were treated 
with T4 combined to rT3. The rT3 inhibition of D2 activity nullified the T4-induced 
apoptosis. Moreover, MuSC derived from Dio2-null mice resulted to be insensitive to 
T4 (Figure 1B). 
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Figure 1. D2 expression causes a dose-dependent apoptosis in proliferating 
myoblasts. 
A. Proliferating MuSC were transiently transfected with D2-WT plasmid at increasing 
doses (50 ng, 500 ng and 2  µg). 48 hours later, cell lysates were collected and PARP 
cleavage was evaluated using western blot analysis. Cells transfected with 
cytomegalovirus served as negative control; tubulin was used as loading control. 
B. Proliferating MuSC from WT and D2KO mice were treated with 30 nM T3, 30 nM 
T4 and 30 nM T4+rT3, respectively. After 24 hours, total proteins were harvested and 
apoptosis induction was detected by western blot showing the cleavage of PARP. 
Tubulin served as loading control. 
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5.2 The TH-induced apoptosis is dependent on TH receptor action 
  To allow a proper expansion, MuSC require lower than circulating T3. To this 
aim, they down-regulate D2 to very low levels. Therefore, we next evaluated the 
expression profile of the other TH signaling cellular regulators in proliferating MuSC. 
We found that TH transporters and TH receptors show markedly reduced expression 
during MuSC proliferation when compared with the differentiating counterpart (Figure 
2). To determine whether the TH-induced apoptosis in proliferating MuSC was directly 
dependent on the action of thyroid hormone receptors (TR), we induced the expression 
of a TR dominant-negative mutant. As showed in Figure 3A, the expression of a TR 
dominant-negative mutant made the proliferating myoblasts insensitive to TH, thus 
showing that the D2-derived T3 directly acts on TR. 
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Figure 2. TH signaling is down-regulated during MuSC proliferation.  
Thyroid receptor α and β (TR α, TR β) and thyroid hormone transporters MCT 8, MCT 
10, OATP 1C1 and OATP 3A1 gene expression was measured by RT-PCR in 
proliferating (PROL) and differentiating (DIFF) MuSC. 
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5.3 The T4 inflow in proliferating myoblasts is mediated by transporters OATP 
1C1 and 3A1  
  We examined the ability of the two major TH, namely T3 and T4, in 
proliferating myoblasts death induction. Surprisingly, proliferating myoblasts were 
insensitive to supraphysiological T3 concentrations, while the treatment with T4 alone 
resulted in massive cell apoptosis (Figure 3B). We speculated that the T3 was not able 
to induce apoptosis due to its inability to cross the cell membrane. To test this 
hypothesis, we transfected proliferating MuSC with a well–known T3 plasma 
transporter, MCT 8. Upon transporter transfection, proliferating cells became sensitive 
to T3 and rapidly apoptosed after T3 treatment (Figure 3C). Furthermore, we 
speculated that the T4 was effective due to the action of a specific T4 transporter 
expressed in proliferating cells. Global gene expression analysis of proliferating and 
differentiated MuSC indicated that these cells express specifically two putative T4 
transporters. To shed light on this issue and on the relative contribution of each of them 
to the T4 action, we used siRNA to specifically knock down OATP 3A1 and 1C1. 
When we subjected cells to a contemporary double specific OATPs 3A1 and 1C1 knock 
down, proliferating MSC became resistant to T4 (Figure 3D). Overall, these 
experiments indicate that the exposure to supraphysiological T4 doses in proliferating 
myoblasts lead to cell apoptosis thanks to the T4 inflow through OATPs 3A1 and 1C1, 
and the subsequent T4 to T3 conversion mediated by D2.  
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Figure 3. MuSC apoptosis relies on T4 inflow through OATPs 1C1 and 3A4 and 
depends on D2-derived T3 action on TH receptor. 
A. Proliferating MuSC were transiently transfected with TR dominant negative plasmid 
and following 24 hours were incubated with 30 nM T4. Following 48 hours, cells 
lysates were collected and PARP cleavage was evaluated using western blot analysis. 
CMV transfected cells served as negative control; tubulin was used as loading control.  
B. Proliferating MuSC were treated with 30 nM T3, 30 nM T4 and 30 nM T3+T4, 
respectively. After 24 hours, cells lysates were harvested and total proteins were 
subjected to western blot analysis of PARP cleavage. The detection of tubulin was used 
as loading control.  
C. Proliferating MuSC were transiently transfected with MCT 8 plasmid and following 
24 hours were incubated with 30 nM T3. Following 48 hours, cells lysates were 
collected and PARP cleavage was evaluated using western blot analysis. Mock 
transfected cells served as negative control; tubulin was used as loading control.  
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D. Proliferating MuSC were subjected to a specific siRNA knock down of OATP 1C1, 
OATP 3A1 and OATP 1C1 + OATP 3A1, respectively. Following 24 hours, cells were 
treated with 30 nM T4 and were harvested after 48 hours. Total proteins were subjected 
to western blot analysis of PARP cleavage; tubulin served as loading control. 
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5.4 Endogenous D2 protein of wild-type and mutated isoforms are dynamically 
located in the endoplasmic reticulum 
  In order to assess whether the T92A polymorphism modifies important 
enzymatic parameters, we investigated the localization of the wild type protein in its 
physiological context. So far, detection of D2 protein and its subcellular localization in 
vivo has been not possible due to the absence of functional antibodies. To overcome this 
problem, we generated a knock-in 3xFlag-D2 mouse, carrying three repetitions of a 
FLAG epitope at the NH2-terminus of the otherwise wild-type enzyme (Figure 4A). 
We confirmed the effective expression of the D2-3xFlag protein by Western blot and 
IP-WB analysis (Figure 4C and D). We used MuSC as a model to address the 
intracellular localization of the D2 protein. Activated MuSC isolated by FACS from the 
D2-3xFlag mouse were grown in culture and D2 expression was evaluated by co-
immunofluorescence analysis. Proliferating cells expressed low levels of D2, mostly 
localized in the cytoplasm, as shown by the double Flag-MyoD staining (Figure 5A). 
D2 partially colocalized with the endoplasmic reticulum (ER) marker calreticulin in 
early differentiating MuSC. Interestingly, D2 was also present in cytoplasmic vesicles 
other than ER (i.e. without calreticulin), but not in the Golgi. During differentiation, D2 
localization changed in parallel with its increased expression. In late differentiated 
myoblasts, D2 expression shifted to perinuclear space (Figure 5B).  
  To determine whether the D2-Ala mutant isoform shared the same subcellular 
localization with the wild type D2, we transfected MuSC from Dio2-null mice with D2-
WT or D2-Ala plasmid and evaluated its cellular localization. Immunofluorescence 
staining showed that both transfected wild type and mutant isoforms localized to the 
cytoplasmic, mainly to the ER (Figure 5C). This expression pattern resembles the 
endogenous protein localization in the same cells. In conclusion, in vivo D2 tracing 
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showed that D2 is dynamically expressed in the ER during proliferation and in the ER-
perinuclear territory during cell differentiation. Importantly, this pattern is identical 
between wild type and the mutant D2-Ala isoform.  
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Figure 4. Generation of knock-in 3xFlag-D2 mouse.  
A. Schematic representation of the modified Dio2 locus gene. Three repetitions of the 
Flag coding sequence were inserted after the ATG codon of the mouse Dio2 gene.  
B. The effective presence of the modified Dio2 gene was confirmed by PCR analysis. 
C. Western blot analysis of tissue protein extracts from different tissues of 3xFlag-D2 
(+) or wild type (-) mice.  
D. Immunoprecipitation with anti-Flag antibody and western blot analysis of protein 
extracts from muscles of 3xFlag-D2 (+) or wild type (-) mice. 
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Figure 5. Intracellular localization of the D2 protein. 
A, B. D2 localizes in the endothelial reticulum and cytoplasmic vesicles in proliferating 
and differentiated MuSC. D2 localization was evaluated by immunofluorescence 
microscopy in FACS-isolated MuSC cultured in proliferative and differentiative 
conditions at different time points. Early proliferative cells were fixed at 12 hours after 
plating and late proliferative cells were fixed 24 hours after plating (A). Differentiation 
was induced 48 hours following plating by replacing growing medium with 
differentiation medium and collected at 12 (early) and 48 hours following medium 
replacement (B). Proliferating cells were co-stained with Flag/MyoD antibodies and 
differentiated cells with Flag/Calreticulin antibodies, as indicated. 
C. Immunofluorescence staining for D2-WT and D2-Ala-Flag (red) and calcireticulin 
(green) and merged images in transiently transfected proliferating MuSC from D2KO 
mice.  
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5.5 D2 Ala-mutant protein has a longer stability than wild-type  
  The SNP T92A falls in a specific 18-amino-acid large loop critical for D2 
recognition by the WSB-1 subunit of E3 ubiquitin ligase. To investigate the 
consequences on D2 stability resulting from the threonine-to-alanine substitution, we 
compared the protein stability of the wild-type and mutant isoforms. We evaluated the 
D2-Ala protein clearance rate in MuSC following rT3 administration, which potently 
accelerate the proteolytic degradation of D2. The D2-Ala protein proved to be even 
more stable under these conditions, showing a longer half-life than wild-type D2 
(Figure 6A and B). Similarly, when the protein biosynthesis inhibitor cycloheximide 
was added to D2-Ala and D2-WT transfected MuSC, D2-Ala clearance was lower than 
that of D2-WT (Figure 6C and D). Cells fractionation showed no differences between 
the wild-type and the mutant isoform subcellular localization, both present in 
microsomes (Figure 6E). 
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Figure 6. D2-Ala protein has a longer stability.  
A. Time course analysis by western blot of D2-WT and D2-Ala after 30, 60 and 120 
minutes rT3 incubation, respectively, 24 hours after transient transfection in 
proliferating MuSC from D2KO mice. D2 was determined using anti-flag antibody; 
tubulin served as loading control.  
B. Time-course western blot results were normalized to tubulin as control, and 
densitometric quantification of bands was determined with the ImageJ software.  
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C. D2-WT and D2-Ala were transiently transfected in proliferating MuSC from D2KO 
mice. Twenty-four hours later, cells were incubated for 40, 80 and 120 minutes with 
cycloheximide. D2 was determined using anti-flag antibody; tubulin served as loading 
control.  
D. Time-course western blot results were normalized to tubulin as control, and bands 
were densitometrically quantified with the ImageJ software.  
E. D2-WT and D2-Ala were transiently transfected in proliferating MuSC from D2KO 
mice. After 24 hours, cells were fractionated into cytosolic (cyto) and ER-containing 
microsomal (micros) fractions. The presence of D2 in the two compartments was 
determined by western blot analysis with anti-flag antibody. KLF and tubulin were used 
as loading controls. 
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5.6 D2-Ala mutant is less efficient than D2-WT in converting T4 into T3 in muscle 
stem cells and pituitary thyrotrophs 
5.6.1 Muscle stem cells model  
  The D2-dependent proapoptotic effect in proliferating myoblasts suggested that 
this cellular model might be a biological sensor with which to quantitatively assess D2-
mediated T4 to T3 conversion. Consequently, we asked whether the D2-Ala mutant 
isoform was equally able to produce T3 than D2-WT, and thus to induce apoptosis. To 
address this question, we transfected proliferating myoblasts from Dio2-null mice with 
D2-WT and D2-Ala. Strikingly, cells expressing the D2-Ala mutant isoform showed 
markedly reduced apoptotic commitment, which suggests a lower intracellular T4 to T3 
conversion by D2-Ala enzyme (Figure 7A). The effect of D2-Ala on apoptosis was 
dose dependent, since transfection with high levels of D2-Ala plasmid induced a 
response similar to obtained with D2-WT (Figure 7B). These data demonstrate that, 
despite a normal subcellular localization and an even slightly higher protein stability, 
the D2-Ala mutant is less efficient than D2-WT in converting T4 into T3 in muscle cells 
in vivo. 
 
5.6.2 Thyrotrophic pituitary cells model 
  To further analyze the the catalytic efficiency of D2-Ala protein in a different 
biological setting where D2-mediated T3 production provokes critical consequences, we 
transfected D2-Ala in primary cultures of pituitary thyrotrophs from Dio2-null mice. 
Thyrotrophs were cultured in TH-free serum and thereafter treated with T4, to 
determine the efficiency of D2-Ala in blocking TSH synthesis. The response to T4-
induced TSH suppression was significantly (P <0.05) lower in thyrotrophs expressing 
D2-Ala than in D2-WT-transfected thyrotrophs (Figure 7C). TSH synthesis directly 
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responds to T3 inhibitory action, that directly derived from transfected D2. Therefore, 
the reduced TSH suppression in thyrotrophs expressing D2-Ala again demonstrates an 
impairment in T4 to T3 conversion by the mutant enzyme. 
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Figure 7. D2-Ala is responsible of a reduced T4 proapoptotic effect on MuSC and a 
decreased TH inhibitory feedback on pituitary thyrotrophs. 
A. Western blot analysis of PARP cleavage in proliferating MuSC from D2KO mice 48 
hours after transfection with D2-WT and D2-Ala, and 24 hours 30 nM T4 incubation, 
respectively. Tubulin served as loading control. 
B. Dose response effect of D2-Ala on apoptosis of proliferating MuSC. MuSC from 
D2KO mice were transiently transfected with 1µg and 3µg of D2-WT and D2-Ala 
plasmid, respectively. 24 hours later, cells were treated with 30 nM T4 and, 48 hours 
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later, total proteins were harvested for western blot analysis of PARP cleavage. Tubulin 
served as loading control. 
C. Time course reverse transcription PCR analysis of β-TSH subunit expression in 
thyrotrophs from D2KO mice, cultured in charcoal-stripped bovine serum and 
transiently transfected with D2-WT and D2-Ala, 16 and 26 hours after 30 nM T4 
incubation, respectively. Non-treated thyrotrophs served as control. 
 
 
  
	 35	
5.7 Comparison of presurgical and postsurgical thyroid hormone levels in patients 
submitted to total thyroidectomy  
  As shown in Table 1, there was no significant difference between presurgery 
and postsurgery serum TSH levels in any subject (by Wilcoxon test for paired data), 
which is consistent with the inclusion criteria and the aim of the study. Despite similar 
TSH levels, mean FT4 levels were slightly but significantly higher (p<0.0001) after 
surgery (10.8 ± 2.2 pg/ml) than before surgery (9.8 ± 2.6 pg/ml). On the contrary, 
postsurgical serum FT3 was significantly lower (p<0.0001) than presurgical FT3 (3.0 ± 
0.35 pg/ml vs 3.3 ± 0.43 pg/ml). Consequently, a significantly lower FT3/FT4 ratio was 
observed in the postsurgical evaluation (0.28 ± 0.06 vs 0.36 ± 0.09; P <0.0001). 
According to the cutoff defined in the “Patients and Methods” section, patients were 
classified as having “reduced FT3” when postsurgical FT3 levels were at least 0.5 
pg/mL lower than presurgical FT3 values. As shown in Figure 8, postsurgery FT3 
levels were lower in a cohort of 48/140 patients (“reduced FT3”, 34.3%), whereas the 
remaining 92 patients ("unchanged FT3 ", 65.7%) had serum FT3 levels identical to the 
presurgical levels. Notably, no differences in sex, age, TSH levels, FT4 levels, LT4 
dose/day and LT4 dose/kg between the two groups of "reduced FT3" and "unchanged 
FT3" were present (Table 2). 
  
	 36	
  TSH FT3 FT4 
  (mUI/L) (pg/ml) (pg/ml) 
Pre-surgical       
      Mean±SD 0.93±0.55 3.3±0.43 9.8±2.6 
      Range 0.10-3.4 2.4-5.4 5.5-17.7 
      Median 0.88 3.3 9.3 
Post-surgical 
         Mean±SD 0.91±0.59 3.0±0.35 10.8±2.2 
      Range 0.01-3.6 1.6-4.1 5.9-18.3 
      Median 0.89 2.9 10.7 
p 0.27 <0.001 <0.001 
pre versus post       
 
Table 1.  
Comparison of presurgical and postsurgical thyroid hormone levels in patients 
submitted to total thyroidectomy. 
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Figure 8.  
Pre-surgical and post-surgical FT3 levels in the “reduced FT3” group (left panel) and in 
the “unchanged FT3” (right panel) group.  
  
p<0.000
1
“FT3 
reduced” 
(n=48) 
P=0.3
4
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(n=92) 
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FT3 reduced 
(n=48) 
FT3 Unchanged 
(n=92) P value 
Post-surgical FT3 (pg/ml) 
      Mean ± SD 
      Range 
      Median 
2.80 ± 0.31 
1.57 - 3.9 
2.8 
3.1 ± 0.32 
2.6 - 4.1 
3.1 
<0.0001 
Post-surgical FT4 (pg/ml) 
      Mean ± SD 
      Range 
      Median 
10.53 ± 2.25 
5.0 - 16.9 
10.0 
11.0 ± 2.1 
7.1 - 18.1 
10.9 
0.17 
Post-surgical TSH  
(mUI/L) 
      Mean ± SD 
      Range 
      Median  
0.98 ± 0.53 
0.13-2.23 
0.98 
0.87 ± 0.62 
0.01 - 3.62 
0.74 
0.12 
Sex 
    Males (n, %) 
    Females (n, %) 
15 (38.4%) 
33 (32.6%) 
24 (61.6%) 
68 (67.4%) 
0.55 
Age (yrs) 
      Mean ± SD 
      Range 
      Median  
55.1 ± 16.0 
24 - 84 
55.5 
54.0 ± 14.4 
18 - 84 
57 
0.67 
LT4 daily dose (mcg) 
      Mean ± SD 
      Range 
      Median  
111.3 ± 30.6 
15 - 175 
112.5 
116.8 ± 25.6 
62 - 175 
112.5 
0.27 
Pro-Kg LT4 dose (mcg) 
      Mean ± SD 
      Range 
      Median  
1.48 ± 0.36 
0.2 - 2.36 
1.5 
1.56 ± 0.33 
0.9 - 2.8 
1.5 
0.17 
 
Table 2.  
Clinical, demographical and biochemical data in “reduced FT3” and “unchanged FT3” 
patients. 
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5.8 Correlation between DIO2 Thr92Ala polymorphism and serum T3 levels in 
athyreotic patients 
  To investigate whether the lower postsurgical FT3 level observed in a subset of 
patients was correlated with the T92A DIO2 gene polymorphism, we analyzed the 
entire coding region and the 5'-UTR regions of DIO2 gene in 102 samples (72.8% of 
enrolled patients) and identified the T92A polymorphism in 63.7% of subjects. In 
particular, 37/102 (36.3%) patients were homozygous wild-type (Thr/Thr), 52/107 
(51.0%) were heterozygous (Ala/Thr) and 13/102 (12.7%) were mutant homozygous 
(Ala/Ala).  
  FT4 levels were significantly higher after surgery than before surgery in the 
Thr/Thr group (11.1 ± 2.4 pg/mL vs 9.5 ± 2.2 pg/mL, P = 0.001) and in the Thr/Ala 
group (10.9 ± 2.0 pg/mL vs 9.9 ± 2.8 pg/mL, P = 0.02), and slightly, but not 
significantly higher in the Ala/Ala group (10.1 ± 1.9 pg/mL vs 9.4 ± 2.6 pg/mL, P = 
0.38). As shown in Table 3, mean postsurgery FT3 levels were significantly lower in 
patients carrying the mutated allele(s) than in wild-type patients (P <0.0001 in the 
Thr/Ala group; P = 0.01 in the Ala/Ala group). Moreover, in wild-type patients FT3 
postsurgical levels were similar to presurgery levels (P = 0.097).  
  To verify these results, we compared pre- and postsurgical changes in FT3 
levels among the three genotype groups. FT3 changes (expressed as the difference 
between pre- and postsurgical FT3 levels) were significantly higher in the Thr/Ala 
group (P <0.05; 95% CI, 0.06038 to 0.5459) and in the Ala/Ala group (P <0.05; 95% 
CI, 0.004411 to 0.7323) than in the Thr/Thr group (Figure 9). On the contrary, TSH, 
FT4, and T3/T4 ratio changes did not differ among the three genotype groups. 
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  Pre-surgical 
FT3 
Post-surgical 
FT3 p 
  (mUI/L) (pg/ml)   
WT       
      Mean±SD 3.2±0.35 3.1±0.36   
      Range 2.4-3.9 2.6-4.1 0.097 
      Median 3.2 3.1   
Thr/Ala 
         Mean±SD 3.4±0.52 3.0±0.35  
      Range 2.7-5.4 1.6-4.1 <0.0001 
      Median 3.3 2.9  
Ala/Ala       
      Mean±SD 3.4±0.37 2.9±0.34   
      Range 2.9-4.2 2.5-3.6 0.01 
      Median 3.4 2.9   
 
Table 3.  
Pre-surgical and post-surgical FT3 levels in relation to the DIO2 genotype. 
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Figure 9.  
Differences between pre-surgical and post-surgical serum FT3 levels in the three 
genotype groups. 
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6 Discussion 
 
  In this study, we provide the first in vivo biological evidence that the D2-Ala 
enzyme is less enzymatically efficient than D2-WT and reduces T3 production in two 
relevant D2-dependent tissues, i.e., skeletal muscle and pituitary thyrotrophs. Previous 
studies analyzed the D2-Ala enzymatic activity, but results are likely to be affected by 
intrinsic artifacts of in vitro assay (67, 73). To overcome the limitations in D2 in vitro 
assay, we used two in vivo systems in intact cells that more closely resemble the in vivo 
situation. Using this approach, we demonstrate that the D2-Ala mutant is less efficient 
in converting T4 into T3. In addiction, we demonstrate the inability of patients carrying 
X/Ala D2 genotype subjected to thyroidectomy to restore adequate T3 levels when 
submitted to LT4 replacement therapy. Former studies analyzed thyroid hormonal 
levels in athyreotic patients genotyped for DIO2 T92A and their respective LT4 intake 
need, but provided conflicting results (13, 63), mainly due to lack of presurgical 
hormonal values and to heterogeneity of study population. The strength of our analysis 
lies in the knowledge of TSH levels prior to thyroidectomy and the similarity of pre- 
and postsurgical TSH value for each patient. Thanks to that, we were able to evaluate 
putative changes in circulating T4 and T3 levels in the same feedback perception from 
HPT axis before and after thyroidectomy. 
  In athyreotic patients on LT4 substitutive therapy, both circulating and 
intracellular T3 levels entirely depend on the deiodinase-mediated T4 to T3 conversion 
(67). However, in approximately 20% of athyreotic patients, LT4 did not ensure 
physiological T3 levels unless suppressing TSH (75), although other studies were 
controversial on this aspect (75, 76). In view of these controversies, we compared 
thyroid hormone levels (TSH, FT3, and FT4) before and after total thyroidectomy in 
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patients on LT4 and with similar TSH levels before and after surgery. We found that 
postoperative FT3 levels were significantly reduced in a subgroup of patients (34.3%), 
even though their TSH levels were in the normal range and similar to those observed 
prior to thyroidectomy. To investigate whether the lower postsurgical FT3 in this subset 
of patients was related to DIO2 gene mutations, we analyzed the entire coding region 
and the 5'-UTR of the DIO2 gene in 102 samples (72.8% of enrolled patients). The 
percentage of reduced postsurgery FT3 levels was directly correlated with the presence 
and severity of the T92A polymorphism: 58.3% in homozygous (Ala/Ala) patients vs 
36.5% in heterozygous (Thr/Ala) subjects. Postoperative FT4 levels did not differ 
among the genotype groups. 
  In our study, we show that pituitary D2-Ala expression determines reduced TH 
suppressive feedback due to impaired enzymatic activity. Since serum TSH did not 
differed before and after thyroidectomy in our cohort of 140 patients, it is somehow 
surprisingly that serum FT3 levels drop down in X/Ala genotype carriers without a 
counterbalancing increase in TSH levels, given equal LT4 daily dose assumption. 
Indeed, median post-thyroidectomy TSH in “FT3 unchanged” group was 0.74 mUI/L 
while was higher in “FT3 reduced” group, i.e. 0.98 mUI/L, although these differences 
did not reached statistical significance (p=0.12). This could be due to the low number of 
patients enrolled, as supported by the study of Torlontano et al. (13), which showed an 
increased need of T4 doses to suppress TSH in thyroidectomized patients carrying the 
D2Ala/Ala mutation. 
  It is reasonable to speculate that in “FT3 reduced” patients, restoration of 
presurgical FT3 value would be obtained at the expense of a higher LT4 intake and a 
subsequently lower TSH level. Nevertheless, the maintenance of suppressed TSH levels 
in athyreotic patients is avoided in the vast majority of hypothyroid patients and is not 
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recommended in order to normalize serum FT3 (64). Moreover, it is recognized that if 
presurgical T3 levels are chosen as therapeutic targets, FT4 levels above the reference 
range are often reached (64). Postsurgical FT4 in “FT3 reduced” group did not showed 
differences from the “FT3 unchanged” group. This is not surprisingly, since in a large 
series by Gullo et al. (75) of athyreotic patients on LT4 monotherapy who were 
compared to TSH-matched euthyroid controls, the finding of FT3 levels below 
reference ranges was not necessarily related to an equal gain in serum FT4. In this 
context, normalization of low FT3 levels in athyreotic patients with higher doses of LT4 
could induce an increase of peripheral D2 degradation and worsen that way 
hypothyroidism in D2-expressing tissues.  
  The evidences of our study strongly support the need of T3+T4 combined 
therapy to restore central and peripheral euthyroidism in the subgroup of athyreotic 
patients who don’t reach normalization of FT3 values with LT4 monotherapy. The 
relationship between low FT3 values and D2-Ala expression in thyroidectomized LT4 
treated patients is supported by the demonstration of a reduced D2-Ala enzymatic 
activity in a biological assay model. 
  A former study founded D2 velocity to be reduced in muscle samples from 
patients homozygous for Ala allele (56). Nevertheless, this evidence was not confirmed 
in other and more recent investigations, suggesting that this results could be related to 
an artifact intrinsic to the classical D2 activity in vitro assay (67). Indeed, with respect 
to muscle tissue, D2 activity measurement might be overestimated due to cell 
homogenates release of iodide that do not correspond to a T4 to T3 enzyme conversion. 
In order to overcome the limitations of D2 in vitro assay, it has been suggested that 
measurements of D2 in intact cells may give more reliable estimates of the in vivo 
situation (73).  
	 45	
  The reliability of our cellular model has been validated by the analysis of wild 
type D2 in the context of new generated D2-3x-flag mouse. By the use of D2-3x-flag 
mouse, we were surprised to observe that functional D2 is even so expressed by a cell 
who does need elevated D3 amounts to guarantee its survival. We demonstrated that 
D2-WT expression in myoblasts is dynamically regulated in the endoplasmic reticulum 
and in perinuclear territory, respectively, during cell proliferation and cell 
differentiation. Significantly, this pattern is maintained by D2-Ala isoform when 
myoblasts are transfected with the mutant protein. A previous report by McAninch et al. 
(61) analyzed D2-Ala expression in HEK-293 transfected cells and revealed consistent 
amount of mutated protein in the Golgi. Our myoblasts model found instead D2-Ala to 
be present in a fashion that similarly traces that of wild type protein, and no amount was 
present in Golgi apparatus. The main difference between these two analyses is that we 
used a physiological model of endogenous protein expression to assess D2 cellular 
compartmentalization, following the D2-WT and D2-Ala protein expression along 
different phases of myoblast maturation. 
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7 Conclusions 
 
We demonstrated for the first time that the T92A DIO2 polymorphism translates into a 
protein with increased half-life, normal subcellular localization but functionally reduced 
enzymatic efficiency in T4 to T3 conversion. Patients carrying the T92A genotype 
undergo a drop in T3 levels after thyroidectomy, not compensated by LT4 replacement 
therapy. The lower plasmatic T3 level associated with the X/Ala D2 genotype suggests 
that a segment of these patients do not respond optimally to standard LT4 replacement 
therapy. Therefore, our study might support the use of combined T4+T3 therapy in the 
subgroup with low serum T3 that carries the T92A DIO2 polymorphism. 
  
	 47	
8 References 
 
1. Fekete, C., and Lechan, R.M. 2014. Central regulation of hypothalamic-pituitary-
thyroid axis under physiological and pathophysiological conditions. Endocr Rev 
35:159-194. 
2. Gereben, B., Zavacki, A.M., Ribich, S., Kim, B.W., Huang, S.A., Simonides, W.S., 
Zeold, A., and Bianco, A.C. 2008. Cellular and molecular basis of deiodinase-
regulated thyroid hormone signaling. Endocr Rev 29:898-938. 
3. Williams, G.R., and Bassett, J.H. 2011. Deiodinases: the balance of thyroid hormone: 
local control of thyroid hormone action: role of type 2 deiodinase. J Endocrinol 
209:261-272. 
4. Maia, A.L., Goemann, I.M., Meyer, E.L., and Wajner, S.M. 2011. Deiodinases: the 
balance of thyroid hormone: type 1 iodothyronine deiodinase in human physiology 
and disease. J Endocrinol 209:283-297. 
5. Arrojo, E.D.R., Fonseca, T.L., Werneck-de-Castro, J.P., and Bianco, A.C. 2013. Role 
of the type 2 iodothyronine deiodinase (D2) in the control of thyroid hormone 
signaling. Biochim Biophys Acta 1830:3956-3964. 
6. Dentice, M., and Salvatore, D. 2011. Deiodinases: the balance of thyroid hormone: 
local impact of thyroid hormone inactivation. J Endocrinol 209:273-282. 
7. Ciavardelli, D., Bellomo, M., Crescimanno, C., and Vella, V. 2014. Type 3 
deiodinase: role in cancer growth, stemness, and metabolism. Front Endocrinol 
(Lausanne) 5:215. 
8. Hoermann, R., Midgley, J.E.M., Larisch, R., and Dietrich, J.W. 2017. Recent 
Advances in Thyroid Hormone Regulation: Toward a New Paradigm for Optimal 
Diagnosis and Treatment. Front Endocrinol (Lausanne) 8:364. 
	 48	
9. Bianco, A.C., and Kim, B.S. 2018. Pathophysiological relevance of deiodinase 
polymorphism. Curr Opin Endocrinol Diabetes Obes 25:341-346. 
10. Mentuccia, D., Thomas, M.J., Coppotelli, G., Reinhart, L.J., Mitchell, B.D., Shuldiner, 
A.R., and Celi, F.S. 2005. The Thr92Ala deiodinase type 2 (DIO2) variant is not 
associated with type 2 diabetes or indices of insulin resistance in the old order of 
Amish. Thyroid 15:1223-1227. 
11. Grarup, N., Andersen, M.K., Andreasen, C.H., Albrechtsen, A., Borch-Johnsen, K., 
Jorgensen, T., Auwerx, J., Schmitz, O., Hansen, T., and Pedersen, O. 2007. Studies of 
the common DIO2 Thr92Ala polymorphism and metabolic phenotypes in 7342 
Danish white subjects. J Clin Endocrinol Metab 92:363-366. 
12. Maia, A.L., Dupuis, J., Manning, A., Liu, C., Meigs, J.B., Cupples, L.A., Larsen, P.R., 
and Fox, C.S. 2007. The type 2 deiodinase (DIO2) A/G polymorphism is not 
associated with glycemic traits: the Framingham Heart Study. Thyroid 17:199-202. 
13. Torlontano, M., Durante, C., Torrente, I., Crocetti, U., Augello, G., Ronga, G., 
Montesano, T., Travascio, L., Verrienti, A., Bruno, R., et al. 2008. Type 2 deiodinase 
polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target 
thyrotropin levels in thyroidectomized patients. J Clin Endocrinol Metab 93:910-913. 
14. Butler, P.W., Smith, S.M., Linderman, J.D., Brychta, R.J., Alberobello, A.T., Dubaz, 
O.M., Luzon, J.A., Skarulis, M.C., Cochran, C.S., Wesley, R.A., et al. 2010. The 
Thr92Ala 5' type 2 deiodinase gene polymorphism is associated with a delayed 
triiodothyronine secretion in response to the thyrotropin-releasing hormone-
stimulation test: a pharmacogenomic study. Thyroid 20:1407-1412. 
15. Panicker, V., Saravanan, P., Vaidya, B., Evans, J., Hattersley, A.T., Frayling, T.M., 
and Dayan, C.M. 2009. Common variation in the DIO2 gene predicts baseline 
	 49	
psychological well-being and response to combination thyroxine plus triiodothyronine 
therapy in hypothyroid patients. J Clin Endocrinol Metab 94:1623-1629. 
16. Wiersinga, W.M. 2017. THERAPY OF ENDOCRINE DISEASE: T4 + T3 
combination therapy: is there a true effect? Eur J Endocrinol 177:R287-R296. 
17. Ortiga-Carvalho, T.M., Sidhaye, A.R., and Wondisford, F.E. 2014. Thyroid hormone 
receptors and resistance to thyroid hormone disorders. Nat Rev Endocrinol 10:582-
591. 
18. Bernal, J., Guadano-Ferraz, A., and Morte, B. 2015. Thyroid hormone transporters-
functions and clinical implications. Nat Rev Endocrinol 11:690. 
19. Visser, W.E., Friesema, E.C., and Visser, T.J. 2011. Minireview: thyroid hormone 
transporters: the knowns and the unknowns. Mol Endocrinol 25:1-14. 
20. van der Deure, W.M., Peeters, R.P., and Visser, T.J. 2010. Molecular aspects of 
thyroid hormone transporters, including MCT8, MCT10, and OATPs, and the effects 
of genetic variation in these transporters. J Mol Endocrinol 44:1-11. 
21. Roef, G.L., Rietzschel, E.R., De Meyer, T., Bekaert, S., De Buyzere, M.L., Van daele, 
C., Toye, K., Kaufman, J.M., and Taes, Y.E. 2013. Associations between single 
nucleotide polymorphisms in thyroid hormone transporter genes (MCT8, MCT10 and 
OATP1C1) and circulating thyroid hormones. Clin Chim Acta 425:227-232. 
22. Ferrara, A.M., Liao, X.H., Gil-Ibanez, P., Marcinkowski, T., Bernal, J., Weiss, R.E., 
Dumitrescu, A.M., and Refetoff, S. 2013. Changes in thyroid status during perinatal 
development of MCT8-deficient male mice. Endocrinology 154:2533-2541. 
23. Lee, J.Y., Kim, M.J., Deliyanti, D., Azari, M.F., Rossello, F., Costin, A., Ramm, G., 
Stanley, E.G., Elefanty, A.G., Wilkinson-Berka, J.L., et al. 2017. Overcoming 
Monocarboxylate Transporter 8 (MCT8)-Deficiency to Promote Human 
Oligodendrocyte Differentiation and Myelination. EBioMedicine 25:122-135. 
	 50	
24. Visser, W.E., Friesema, E.C., Jansen, J., and Visser, T.J. 2007. Thyroid hormone 
transport by monocarboxylate transporters. Best Pract Res Clin Endocrinol Metab 
21:223-236. 
25. Hagenbuch, B. 2007. Cellular entry of thyroid hormones by organic anion transporting 
polypeptides. Best Pract Res Clin Endocrinol Metab 21:209-221. 
26. Mayerl, S., Visser, T.J., Darras, V.M., Horn, S., and Heuer, H. 2012. Impact of 
Oatp1c1 deficiency on thyroid hormone metabolism and action in the mouse brain. 
Endocrinology 153:1528-1537. 
27. Kim, B.W., Zavacki, A.M., Curcio-Morelli, C., Dentice, M., Harney, J.W., Larsen, 
P.R., and Bianco, A.C. 2003. Endoplasmic reticulum-associated degradation of the 
human type 2 iodothyronine deiodinase (D2) is mediated via an association between 
mammalian UBC7 and the carboxyl region of D2. Mol Endocrinol 17:2603-2612. 
28. Werneck de Castro, J.P., Fonseca, T.L., Ueta, C.B., McAninch, E.A., Abdalla, S., 
Wittmann, G., Lechan, R.M., Gereben, B., and Bianco, A.C. 2015. Differences in 
hypothalamic type 2 deiodinase ubiquitination explain localized sensitivity to 
thyroxine. J Clin Invest 125:769-781. 
29. Murakami, M., Araki, O., Hosoi, Y., Kamiya, Y., Morimura, T., Ogiwara, T., 
Mizuma, H., and Mori, M. 2001. Expression and regulation of type II iodothyronine 
deiodinase in human thyroid gland. Endocrinology 142:2961-2967. 
30. Sagar, G.D., Gereben, B., Callebaut, I., Mornon, J.P., Zeold, A., Curcio-Morelli, C., 
Harney, J.W., Luongo, C., Mulcahey, M.A., Larsen, P.R., et al. 2008. The thyroid 
hormone-inactivating deiodinase functions as a homodimer. Mol Endocrinol 22:1382-
1393. 
31. Koenig, R.J. 2005. Regulation of type 1 iodothyronine deiodinase in health and 
disease. Thyroid 15:835-840. 
	 51	
32. Bianco, A.C., Salvatore, D., Gereben, B., Berry, M.J., and Larsen, P.R. 2002. 
Biochemistry, cellular and molecular biology, and physiological roles of the 
iodothyronine selenodeiodinases. Endocr Rev 23:38-89. 
33. Singh, B.K., Sinha, R.A., and Yen, P.M. 2018. Novel Transcriptional Mechanisms for 
Regulating Metabolism by Thyroid Hormone. Int J Mol Sci 19. 
34. Cheng, S.Y., Leonard, J.L., and Davis, P.J. 2010. Molecular aspects of thyroid 
hormone actions. Endocr Rev 31:139-170. 
35. Cheng, S.Y. 2005. Thyroid hormone receptor mutations and disease: beyond thyroid 
hormone resistance. Trends Endocrinol Metab 16:176-182. 
36. Darras, V.M., Houbrechts, A.M., and Van Herck, S.L. 2015. Intracellular thyroid 
hormone metabolism as a local regulator of nuclear thyroid hormone receptor-
mediated impact on vertebrate development. Biochim Biophys Acta 1849:130-141. 
37. Astapova, I. 2016. Role of co-regulators in metabolic and transcriptional actions of 
thyroid hormone. J Mol Endocrinol 56:73-97. 
38. Salvatore, D., Simonides, W.S., Dentice, M., Zavacki, A.M., and Larsen, P.R. 2014. 
Thyroid hormones and skeletal muscle--new insights and potential implications. Nat 
Rev Endocrinol 10:206-214. 
39. Simonides, W.S., and van Hardeveld, C. 2008. Thyroid hormone as a determinant of 
metabolic and contractile phenotype of skeletal muscle. Thyroid 18:205-216. 
40. Bloise, F.F., Cordeiro, A., and Ortiga-Carvalho, T.M. 2018. Role of thyroid hormone 
in skeletal muscle physiology. J Endocrinol 236:R57-R68. 
41. Seale, P., and Rudnicki, M.A. 2000. A new look at the origin, function, and "stem-
cell" status of muscle satellite cells. Dev Biol 218:115-124. 
42. Buckingham, M., and Relaix, F. 2015. PAX3 and PAX7 as upstream regulators of 
myogenesis. Semin Cell Dev Biol 44:115-125. 
	 52	
43. Fukada, S., Ma, Y., Ohtani, T., Watanabe, Y., Murakami, S., and Yamaguchi, M. 
2013. Isolation, characterization, and molecular regulation of muscle stem cells. Front 
Physiol 4:317. 
44. Seale, P., Sabourin, L.A., Girgis-Gabardo, A., Mansouri, A., Gruss, P., and Rudnicki, 
M.A. 2000. Pax7 is required for the specification of myogenic satellite cells. Cell 
102:777-786. 
45. Muscat, G.E., Downes, M., and Dowhan, D.H. 1995. Regulation of vertebrate muscle 
differentiation by thyroid hormone: the role of the myoD gene family. Bioessays 
17:211-218. 
46. Wang, Y.X., and Rudnicki, M.A. 2012. Satellite cells, the engines of muscle repair. 
Nat Rev Mol Cell Biol 13:127-133. 
47. Marsili, A., Tang, D., Harney, J.W., Singh, P., Zavacki, A.M., Dentice, M., Salvatore, 
D., and Larsen, P.R. 2011. Type II iodothyronine deiodinase provides intracellular 
3,5,3'-triiodothyronine to normal and regenerating mouse skeletal muscle. Am J 
Physiol Endocrinol Metab 301:E818-824. 
48. Dentice, M., Marsili, A., Zavacki, A., Larsen, P.R., and Salvatore, D. 2013. The 
deiodinases and the control of intracellular thyroid hormone signaling during cellular 
differentiation. Biochim Biophys Acta 1830:3937-3945. 
49. Clement, K., Viguerie, N., Diehn, M., Alizadeh, A., Barbe, P., Thalamas, C., Storey, 
J.D., Brown, P.O., Barsh, G.S., and Langin, D. 2002. In vivo regulation of human 
skeletal muscle gene expression by thyroid hormone. Genome Res 12:281-291. 
50. Soukup, T., and Smerdu, V. 2015. Effect of altered innervation and thyroid hormones 
on myosin heavy chain expression and fiber type transitions: a mini-review. 
Histochem Cell Biol 143:123-130. 
	 53	
51. Ambrosio, R., De Stefano, M.A., Di Girolamo, D., and Salvatore, D. 2017. Thyroid 
hormone signaling and deiodinase actions in muscle stem/progenitor cells. Mol Cell 
Endocrinol 459:79-83. 
52. Dentice, M., Ambrosio, R., Damiano, V., Sibilio, A., Luongo, C., Guardiola, O., 
Yennek, S., Zordan, P., Minchiotti, G., Colao, A., et al. 2014. Intracellular inactivation 
of thyroid hormone is a survival mechanism for muscle stem cell proliferation and 
lineage progression. Cell Metab 20:1038-1048. 
53. Salvatore, D. 2018. Deiodinases and stem cells: an intimate relationship. J Endocrinol 
Invest 41:59-66. 
54. Dentice, M., Marsili, A., Ambrosio, R., Guardiola, O., Sibilio, A., Paik, J.H., 
Minchiotti, G., DePinho, R.A., Fenzi, G., Larsen, P.R., et al. 2010. The FoxO3/type 2 
deiodinase pathway is required for normal mouse myogenesis and muscle 
regeneration. J Clin Invest 120:4021-4030. 
55. Mentuccia, D., Proietti-Pannunzi, L., Tanner, K., Bacci, V., Pollin, T.I., Poehlman, 
E.T., Shuldiner, A.R., and Celi, F.S. 2002. Association between a novel variant of the 
human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of 
interaction with the Trp64Arg variant of the beta-3-adrenergic receptor. Diabetes 
51:880-883. 
56. Canani, L.H., Capp, C., Dora, J.M., Meyer, E.L., Wagner, M.S., Harney, J.W., Larsen, 
P.R., Gross, J.L., Bianco, A.C., and Maia, A.L. 2005. The type 2 deiodinase A/G 
(Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased 
insulin resistance in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 
90:3472-3478. 
	 54	
57. Dora, J.M., Machado, W.E., Rheinheimer, J., Crispim, D., and Maia, A.L. 2010. 
Association of the type 2 deiodinase Thr92Ala polymorphism with type 2 diabetes: 
case-control study and meta-analysis. Eur J Endocrinol 163:427-434. 
58. Grineva, E., Babenko, A., Vahrameeva, N., Bogdanova, M., Kostareva, A., Popcova, 
D., and Larionova, V. 2009. Type 2 deiodinase Thr92Ala polymorphism impact on 
clinical course and myocardial remodeling in patients with Graves' disease. Cell Cycle 
8:2565-2569. 
59. He, B., Li, J., Wang, G., Ju, W., Lu, Y., Shi, Y., He, L., and Zhong, N. 2009. 
Association of genetic polymorphisms in the type II deiodinase gene with bipolar 
disorder in a subset of Chinese population. Prog Neuropsychopharmacol Biol 
Psychiatry 33:986-990. 
60. Peeters, R.P., van Toor, H., Klootwijk, W., de Rijke, Y.B., Kuiper, G.G., Uitterlinden, 
A.G., and Visser, T.J. 2003. Polymorphisms in thyroid hormone pathway genes are 
associated with plasma TSH and iodothyronine levels in healthy subjects. J Clin 
Endocrinol Metab 88:2880-2888. 
61. McAninch, E.A., Jo, S., Preite, N.Z., Farkas, E., Mohacsik, P., Fekete, C., Egri, P., 
Gereben, B., Li, Y., Deng, Y., et al. 2015. Prevalent polymorphism in thyroid 
hormone-activating enzyme leaves a genetic fingerprint that underlies associated 
clinical syndromes. J Clin Endocrinol Metab 100:920-933. 
62. Zhang, X., Sun, J., Han, W., Jiang, Y., Peng, S., Shan, Z., and Teng, W. 2016. The 
Type 2 Deiodinase Thr92Ala Polymorphism Is Associated with Worse Glycemic 
Control in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-
Analysis. J Diabetes Res 2016:5928726. 
63. Heemstra, K.A., Hoftijzer, H.C., van der Deure, W.M., Peeters, R.P., Fliers, E., 
Appelhof, B.C., Wiersinga, W.M., Corssmit, E.P., Visser, T.J., and Smit, J.W. 2009. 
	 55	
Thr92Ala polymorphism in the type 2 deiodinase is not associated with T4 dose in 
athyroid patients or patients with Hashimoto thyroiditis. Clin Endocrinol (Oxf) 
71:279-283. 
64. Jonklaas, J., Bianco, A.C., Bauer, A.J., Burman, K.D., Cappola, A.R., Celi, F.S., 
Cooper, D.S., Kim, B.W., Peeters, R.P., Rosenthal, M.S., et al. 2014. Guidelines for 
the treatment of hypothyroidism: prepared by the american thyroid association task 
force on thyroid hormone replacement. Thyroid 24:1670-1751. 
65. Wartofsky, L. 2013. Combination L-T3 and L-T4 therapy for hypothyroidism. Curr 
Opin Endocrinol Diabetes Obes 20:460-466. 
66. Wiersinga, W.M., Duntas, L., Fadeyev, V., Nygaard, B., and Vanderpump, M.P. 2012. 
2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism. 
Eur Thyroid J 1:55-71. 
67. Acosta, B.M., and Bianco, A.C. 2010. New insights into thyroid hormone replacement 
therapy. F1000 Med Rep 2. 
68. Wekking, E.M., Appelhof, B.C., Fliers, E., Schene, A.H., Huyser, J., Tijssen, J.G., and 
Wiersinga, W.M. 2005. Cognitive functioning and well-being in euthyroid patients on 
thyroxine replacement therapy for primary hypothyroidism. Eur J Endocrinol 
153:747-753. 
69. Heemstra, K.A., Hoftijzer, H., van der Deure, W.M., Peeters, R.P., Hamdy, N.A., 
Pereira, A., Corssmit, E.P., Romijn, J.A., Visser, T.J., and Smit, J.W. 2010. The type 2 
deiodinase Thr92Ala polymorphism is associated with increased bone turnover and 
decreased femoral neck bone mineral density. J Bone Miner Res 25:1385-1391. 
70. Nair, S., Muller, Y.L., Ortega, E., Kobes, S., Bogardus, C., and Baier, L.J. 2012. 
Association analyses of variants in the DIO2 gene with early-onset type 2 diabetes 
mellitus in Pima Indians. Thyroid 22:80-87. 
	 56	
71. Alina, B., Daria, P., Olga, F., Vladislav, S., Anna, K., and Elena, G. 2012. Thr92Ala 
polymorphism of human type 2 deiodinase gene (hD2) affects the development of 
Graves' disease, treatment efficiency, and rate of remission. Clin Dev Immunol 
2012:340542. 
72. de Jong, F.J., Peeters, R.P., den Heijer, T., van der Deure, W.M., Hofman, A., 
Uitterlinden, A.G., Visser, T.J., and Breteler, M.M. 2007. The association of 
polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone 
parameters and atrophy of the medial temporal lobe. J Clin Endocrinol Metab 92:636-
640. 
73. Larsen, P.R. 2009. Type 2 iodothyronine deiodinase in human skeletal muscle: new 
insights into its physiological role and regulation. J Clin Endocrinol Metab 94:1893-
1895. 
74. Luongo, C., Martin, C., Vella, K., Marsili, A., Ambrosio, R., Dentice, M., Harney, 
J.W., Salvatore, D., Zavacki, A.M., and Larsen, P.R. 2015. The selective loss of the 
type 2 iodothyronine deiodinase in mouse thyrotrophs increases basal TSH but blunts 
the thyrotropin response to hypothyroidism. Endocrinology 156:745-754. 
75. Gullo, D., Latina, A., Frasca, F., Le Moli, R., Pellegriti, G., and Vigneri, R. 2011. 
Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients. 
PLoS One 6:e22552. 
76. Jonklaas, J., Davidson, B., Bhagat, S., and Soldin, S.J. 2008. Triiodothyronine levels 
in athyreotic individuals during levothyroxine therapy. JAMA 299:769-777. 
 
 
